Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2019
Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1
Sannai M, Doneddu V, Giri V, Seeholzer S, Nicolas E, Yip S, Bassi M, Mancuso P, Cortellino S, Cigliano A, Lurie R, Ding H, Chernoff J, Sobol R, Yen T, Bagella L, Bellacosa A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. DNA Repair 2019, 82: 102687. PMID: 31476572, PMCID: PMC6785017, DOI: 10.1016/j.dnarep.2019.102687.Peer-Reviewed Original ResearchConceptsTandem affinity purificationDNA damage responseSumoylation sitesDamage responseDNA mismatch repair protein MLH1Mismatch repair protein MLH1Main SUMOylation siteCalmodulin affinity columnTranscriptional regulationHEK-293 cellsGenomic stabilityNovel proteinCancer Genome AtlasGlycosylase activitySUMOylationProtein MLH1Affinity purificationMBD4CpG sitesU mismatchesUnmodified speciesRepair activityMissense mutationsGenome AtlasHEK-293
2016
Familial prostate cancer
Giri V, Beebe-Dimmer J. Familial prostate cancer. Seminars In Oncology 2016, 43: 560-565. PMID: 27899188, PMCID: PMC6986340, DOI: 10.1053/j.seminoncol.2016.08.001.Peer-Reviewed Original ResearchConceptsFamilial prostate cancerProstate cancer riskProstate cancerHereditary prostate cancerBRCA2 mutationsFamily historyCancer riskNational Comprehensive Cancer Network guidelinesGenetic testingProstate cancer screeningFamily cancer historyProstate cancer patientsEarly-onset diseasePositive family historyFirst-degree relativesClustering of casesNetwork guidelinesColorectal cancerCancer historyCancer patientsCancer screeningCommon tumorsRisk factorsSurrogate markerOvarian cancer
2015
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer
Nicolas E, Arora S, Zhou Y, Serebriiskii I, Andrake M, Handorf E, Bodian D, Vockley J, Dunbrack R, Ross E, Egleston B, Hall M, Golemis E, Giri V, Daly M. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget 2015, 6: 39614-39633. PMID: 26485759, PMCID: PMC4741850, DOI: 10.18632/oncotarget.5554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicCells, CulturedDNA Breaks, Double-StrandedDNA RepairEtoposideExomeFamily HealthGenetic Predisposition to DiseaseHistonesHumansINDEL MutationMaleMiddle AgedMutationPolymorphism, Single NucleotideProstatic NeoplasmsRisk AssessmentRisk FactorsSequence Analysis, DNAT-Lymphocytes
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2013
Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer
Handorf E, Crumpler N, Gross L, Giri V. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal Of Genetic Counseling 2013, 23: 371-376. PMID: 24310616, PMCID: PMC4028414, DOI: 10.1007/s10897-013-9672-5.Peer-Reviewed Original ResearchConceptsHOXB13 G84E mutationProstate cancerG84E mutationFamily historyProstate cancer screening programsCancer screening programsProstate cancer screeningProstate cancer riskHigh-risk menMen ages 35HOXB13 G84ECancer screeningExact binomial confidence intervalsMutation carriersScreening programAge 35Cancer riskClinical utilityUnaffected menPrevalence estimatesGenetic testingPrevalenceCancerConfidence intervalsGenetic counseling